Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prime MedicinePRME -2.52%32 3-Year EPS without NRI Growth Rate is 30.00% as of Jun. 2026, which is 186% above its 10-year median of 10.50. GuruFocus rates PRME with a GF Scoreâ„¢ of 32/100. The stock has 3 warning signs investors should review. Among 1,161 Biotechnology companies, Prime Medicine ranks better than 66.32% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 30.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -29.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Prime Medicine was 30.00% per year. The lowest was -133.30% per year. And the median was 10.50% per year.
Prime Medicine (NAS:PRME) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Prime Medicine 3-Year EPS without NRI Growth Rate Related Terms
PRME vs VSTM, ALT, FDMT: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Prime Medicine's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Prime Medicine's 3-Year EPS without NRI Growth Rate falls into.
Prime Medicine 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 30.00% mean?
Prime Medicine (PRME) has a 3-Year EPS without NRI Growth Rate of 30.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Prime Medicine and its competitors. This is 186% above median its historical median of 10.50. According to the industry distribution chart, Prime Medicine ranks #391 out of 1161 companies in the Biotechnology industry, placing it in the top 33.7%.
Is Prime Medicine's 3-Year EPS without NRI Growth Rate too high?
Prime Medicine's current 3-Year EPS without NRI Growth Rate of 30.00% is 186% above median its 10-year median of 10.50. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Prime Medicine's value of 30.00% is 85.2% above this industry median. Based on the distribution chart, Prime Medicine ranks #391 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prime Medicine has a GF Scoreâ„¢ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's 3-Year EPS without NRI Growth Rate compare to VSTM and ALT?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #391 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This puts Prime Medicine in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Prime Medicine's value of 30.00% is 85.2% above this benchmark. While the company's 10-year median is 10.50 vs. the industry median of 16.20, Prime Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current 3-Year EPS without NRI Growth Rate of 30.00% is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Prime Medicine and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current 3-Year EPS without NRI Growth Rate is 30.00%, which is 186% above median its own 10-year median of 10.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current 3-Year EPS without NRI Growth Rate of 30.00%. The current 3-Year EPS without NRI Growth Rate is 30.00%, which is 186% above median its 10-year median of 10.50 and 85.2% above the Biotechnology industry median of 16.20. Prime Medicine's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Prime Medicine (PRME), the current 3-Year EPS without NRI Growth Rate is 30.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
32GF Score
Get the complete analysis for PRME
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
